(EYPT) Eyepoint Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 991m USD | Total Return: 130.9% in 12m

Retinal Therapeutics, Drug Delivery, Sustained Release, Biopharmaceuticals
Total Rating 31
Safety 33
Buy Signal -1.44
Biotechnology
Industry Rotation: -8.2
Market Cap: 991M
Avg Turnover: 10.2M
Risk 3d forecast
Volatility84.0%
VaR 5th Pctl13.1%
VaR vs Median-5.21%
Reward TTM
Sharpe Ratio1.40
Rel. Str. IBD64.2
Rel. Str. Peer Group59.1
Character TTM
Beta0.845
Beta Downside0.570
Hurst Exponent0.572
Drawdowns 3y
Max DD86.10%
CAGR/Max DD0.34
CAGR/Mean DD0.58
EPS (Earnings per Share) EPS (Earnings per Share) of EYPT over the last years for every Quarter: "2021-03": -0.5, "2021-06": -0.35, "2021-09": -0.58, "2021-12": -0.59, "2022-03": -0.56, "2022-06": -0.52, "2022-09": -0.49, "2022-12": -1.16, "2023-03": -0.56, "2023-06": -0.61, "2023-09": -0.33, "2023-12": -0.33, "2024-03": -0.55, "2024-06": -0.58, "2024-09": -0.54, "2024-12": -0.64, "2025-03": -0.65, "2025-06": -0.85, "2025-09": -0.85, "2025-12": -0.81, "2026-03": -0.99,
Last SUE: -2.30
Qual. Beats: -1
Revenue Revenue of EYPT over the last years for every Quarter: 2021-03: 7.323, 2021-06: 9.013, 2021-09: 9.059, 2021-12: 11.544, 2022-03: 9.294, 2022-06: 11.565, 2022-09: 10.012, 2022-12: 10.533, 2023-03: 7.683, 2023-06: 9.105, 2023-09: 15.202, 2023-12: 14.028, 2024-03: 11.684, 2024-06: 9.477, 2024-09: 10.524, 2024-12: 11.588, 2025-03: 24.453, 2025-06: 5.333, 2025-09: 0.966, 2025-12: 0.62, 2026-03: 0.696,
Rev. CAGR: -24.78%
Rev. Trend: -48.1%
Last SUE: 0.06
Qual. Beats: 0

Warnings

Share dilution 23.3% YoY

Interest Coverage Ratio -8540.1 is critical

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Altman Z'' -10.26 < 1.0 - financial distress zone

Volatile Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: EYPT Eyepoint Pharmaceuticals

EyePoint, Inc. (EYPT) is a clinical-stage pharmaceutical company specializing in the development of sustained-release therapeutics for chronic retinal diseases. The company utilizes its proprietary Durasert E bioerodible technology to deliver medication directly into the eye over extended periods, aiming to reduce the frequency of invasive intraocular injections. This business model focuses on high-barrier-to-entry drug delivery systems within the specialized ophthalmology sector.

The firm’s primary asset, DURAVYU, is a tyrosine kinase inhibitor currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The pipeline also includes EYP-2301, a pre-clinical TIE-2 agonist targeting additional retinal pathologies. The retinal disease market is characterized by high patient volumes and a continuous demand for treatments that improve long-term compliance through extended dosing intervals.

For more detailed insights into these clinical developments, explore the latest data on ValueRay. Founded in 2000 and headquartered in Watertown, Massachusetts, the company rebranded from EyePoint Pharmaceuticals, Inc. to EyePoint, Inc. in late 2025.

Headlines to Watch Out For
  • DURAVYU Phase 3 clinical trial results drive long-term valuation for wet AMD treatment
  • Commercial success of Durasert E technology determines future licensing and royalty revenue
  • FDA regulatory approval timeline for vorolanib impacts market entry and investor confidence
  • Cash runway and R&D expenditures influence potential for future equity dilution
  • Competition from established anti-VEGF therapies affects projected market share in retinal disease segment
Piotroski VR-10 (Strict) 1.0
Net Income: -271.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.94 > 0.02 and ΔFCF/TA -52.48 > 1.0
NWC/Revenue: 2.78k% < 20% (prev 509.1%; Δ 2.28k% < -1%)
CFO/TA -0.93 > 3% & CFO -267.5m > Net Income -271.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.66 > 1.5 & < 3
Outstanding Shares: last quarter (86.0m) vs 12m ago 23.27% < -2%
Gross Margin: 76.51% > 18% (prev 0.93%; Δ 7.56k% > 0.5%)
Asset Turnover: 2.34% > 50% (prev 15.46%; Δ -13.12% > 0%)
Interest Coverage Ratio: -8.54k > 6 (EBITDA TTM -279.4m / Interest Expense TTM 33.0k)
Altman Z'' -10.26
A: 0.74 (Total Current Assets 249.5m - Total Current Liabilities 37.5m) / Total Assets 288.2m
B: -4.13 (Retained Earnings -1.19b / Total Assets 288.2m)
C: -0.87 (EBIT TTM -281.8m / Avg Total Assets 325.4m)
D: 3.99 (Book Value of Equity 230.5m / Total Liabilities 57.7m)
Altman-Z'' = -10.26 = D
Beneish M 1.00
DSRI: 19.26 (Receivables 1.16m/442k, Revenue 7.62m/56.0m)
GMI: 1.22 (GM 76.51% / 93.29%)
AQI: 3.95 (AQ_t 0.07 / AQ_t-1 0.02)
SGI: 0.14 (Revenue 7.62m / 56.0m)
TATA: -0.01 (NI -271.6m - CFO -267.5m) / TA 288.2m)
Beneish M = 13.32 (Cap -4..+1) = D
What is the price of EYPT shares?

As of May 24, 2026, the stock is trading at USD 12.78 with a total of 517,155 shares traded.
Over the past week, the price has changed by +4.70%, over one month by -9.20%, over three months by -24.25% and over the past year by +130.89%.

Is EYPT a buy, sell or hold?

Eyepoint Pharmaceuticals has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy EYPT.

  • StrongBuy: 9
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the EYPT price?
Analysts Target Price 37 189.5%
Eyepoint Pharmaceuticals (EYPT) - Fundamental Data Overview as of 21 May 2026
P/E Forward = 6.1614
P/S = 130.1555
P/B = 4.4891
Revenue TTM = 7.62m USD
EBIT TTM = -281.8m USD
EBITDA TTM = -279.4m USD
 Long Term Debt = unknown (none)
 Short Term Debt = unknown (none)
 Debt = 20.2m USD (from shortLongTermDebtTotal, last quarter) (leases 20.2m already included)
Net Debt = -202.3m USD (calculated: Debt 20.2m - CCE 222.5m)
Enterprise Value = 788.7m USD (991.0m + Debt 20.2m - CCE 222.5m)
Interest Coverage Ratio = -8.54k (Ebit TTM -281.8m / Interest Expense TTM 33.0k)
EV/FCF = -2.90x (Enterprise Value 788.7m / FCF TTM -271.5m)
FCF Yield = -34.43% (FCF TTM -271.5m / Enterprise Value 788.7m)
 FCF Margin = -3.57k% (FCF TTM -271.5m / Revenue TTM 7.62m)
 Net Margin = -3.57k% (Net Income TTM -271.6m / Revenue TTM 7.62m)
 Gross Margin = 76.51% ((Revenue TTM 7.62m - Cost of Revenue TTM 1.79m) / Revenue TTM)
Gross Margin QoQ = 24.14% (prev 39.52%)
Tobins Q-Ratio = 2.74 (Enterprise Value 788.7m / Total Assets 288.2m)
Interest Expense / Debt = 0.16% (Interest Expense 33.0k / Debt 20.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -222.6m (EBIT -281.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.66 (Total Current Assets 249.5m / Total Current Liabilities 37.5m)
Debt / Equity = 0.09 (Debt 20.2m / totalStockholderEquity, last quarter 230.5m)
 Debt / EBITDA = 0.72 (negative EBITDA) (Net Debt -202.3m / EBITDA -279.4m)
 Debt / FCF = 0.75 (negative FCF - burning cash) (Net Debt -202.3m / FCF TTM -271.5m)
 Total Stockholder Equity = 245.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -83.47% (Net Income -271.6m / Total Assets 288.2m)
RoE = -18.92% (Net Income TTM -271.6m / Total Stockholder Equity 1.44b)
 RoCE = -112.4% (out of range, set to none) (EBIT -281.8m / Capital Employed (Total Assets 288.2m - Current Liab 37.5m))
 RoIC = -88.79% (negative operating profit) (NOPAT -222.6m / Invested Capital 250.8m)
 WACC = 8.77% (E(991.0m)/V(1.01b) * Re(8.95%) + D(20.2m)/V(1.01b) * Rd(0.16%) * (1-Tc(0.21)))
Discount Rate = 8.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 37.27%
 [DCF] Fair Price = unknown (Cash Flow -271.5m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.30 | # QB: -1
Revenue Correlation: -48.09 | Revenue CAGR: -24.78% | SUE: 0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.92 | Chg30d=-10.32% | Revisions=-50% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.80 | Chg30d=-3.90% | Revisions=-40% | Analysts=10
EPS current Year (2026-12-31): EPS=-3.47 | Chg30d=-7.76% | Revisions=-33% | GrowthEPS=-9.5% | GrowthRev=-94.6%
EPS next Year (2027-12-31): EPS=-2.84 | Chg30d=-3.37% | Revisions=-27% | GrowthEPS=+18.3% | GrowthRev=+2735.6%
[Analyst] Revisions Ratio: -50%